Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and Pembrolizumab in Advanced/Metastatic Soft-tissue Sarcoma
NCT07283731Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07283731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283731.